Department of Dermatology, Seoul National University College of Medicine, Korea.
Acta Derm Venereol. 2011 Jan;91(1):40-3. doi: 10.2340/00015555-0995.
Narrowband ultraviolet B (nbUVB) phototherapy is used around the world for the treatment of various skin diseases. However, the carcinogenic risk associated with nbUVB treatment in patients with skin phototypes III-V has not been studied. This retrospective study compared the incidence of skin cancer in Korean patients with skin phototypes III-V treated with nbUVB with that in a control Korean population. A total of 445 nbUVB-treated patients were followed for 1,274 person-years (mean follow-up period 34.4 months). No melanoma cases were detected during the follow-up period. How-ever, one patient developed basal cell carcinoma four months after the start of nbUVB phototherapy. For non-melanoma skin cancer, the expected number of cases was 0.059 and the standardized incidence ratio 17.0 (95% confidence interval 0.4-94.8). There were no statistically significant differences between the nbUVB and control groups. Thus, nbUVB phototherapy using TL-01 lamps seems to be a safe therapeutic modality for patients with skin phototypes III-V.
窄谱中波紫外线(nbUVB)光疗在全球范围内用于治疗各种皮肤疾病。然而,皮肤光型 III-V 患者接受 nbUVB 治疗的致癌风险尚未得到研究。本回顾性研究比较了韩国皮肤光型 III-V 患者接受 nbUVB 治疗与韩国对照组人群的皮肤癌发病率。共有 445 名 nbUVB 治疗患者接受了 1274 人年的随访(平均随访期 34.4 个月)。随访期间未发现黑色素瘤病例。然而,有 1 例患者在开始 nbUVB 光疗后 4 个月发生基底细胞癌。对于非黑色素瘤皮肤癌,预期病例数为 0.059,标准化发病比为 17.0(95%置信区间 0.4-94.8)。nbUVB 组和对照组之间无统计学差异。因此,使用 TL-01 灯的 nbUVB 光疗似乎是皮肤光型 III-V 患者的一种安全治疗方式。